Search Results

You are looking at 1 - 10 of 272 items for :

  • "pediatric" x
  • All content x
Clear All
Full access

Paul D. Harker-Murray, Lauren Pommert, and Matthew J. Barth

As a group, lymphomas are the third most frequent malignancy in pediatric patients. Mature B-cell non-Hodgkin lymphomas (B-NHLs) constitute approximately 60% of all pediatric NHL diagnoses and 7% of all pediatric cancers. Most pediatric B-NHLs are

Full access

Damon Reed, Rebecca G. Block, and Rebecca Johnson

, guidelines, and criteria. This article describes the development of 2 AYA programs built as extensions of either medical oncology or pediatric oncology programs. It reviews key program elements based on both the experiences of the individual programs and the

Full access

Steven G. Waguespack and Gary Francis

contrast as part of their preoperative staging, waiting 2 to 3 months or confirming normal 24-hour urinary iodine values before performing a diagnostic thyroid scan is advisable. Figure 2 Approach to surveillance and treatment in pediatric patients

Full access

Kimberly Davies, Matthew Barth, Saro Armenian, Anthony N. Audino, Phillip Barnette, Branko Cuglievan, Hilda Ding, James B. Ford, Paul J. Galardy, Rebecca Gardner, Rabi Hanna, Robert Hayashi, Alexandra E. Kovach, Andrea Judit Machnitz, Kelly W. Maloney, Lianna Marks, Kristin Page, Anne F. Reilly, Joanna L. Weinstein, Ana C. Xavier, Nicole R. McMillian, and Deborah A. Freedman-Cass

% of cancers, whereas in adolescents aged 15 to 19 years, NHL accounts for 7%. 1 The 5‐year relative survival rates for patients with NHL in these age groups are 91% and 88%, respectively. 1 Pediatric aggressive mature B-cell lymphomas are the most

Full access

Patrick Brown, Hiroto Inaba, Colleen Annesley, Jill Beck, Susan Colace, Mari Dallas, Kenneth DeSantes, Kara Kelly, Carrie Kitko, Norman Lacayo, Nicole Larrier, Luke Maese, Kris Mahadeo, Ronica Nanda, Valentina Nardi, Vilmarie Rodriguez, Jenna Rossoff, Laura Schuettpelz, Lewis Silverman, Jessica Sun, Weili Sun, David Teachey, Victor Wong, Gregory Yanik, Alyse Johnson-Chilla, and Ndiya Ogba

United States is 1.38 per 100,000 individuals per year, 1 with approximately 5,930 new cases and 1,500 deaths estimated in 2019. 2 It is also the most common pediatric malignancy, representing 75%–80% of acute leukemias among children. 3 The median age

Full access

Deena R. Levine, Liza-Marie Johnson, Angela Snyder, Robert K. Wiser, Deborah Gibson, Javier R. Kane, and Justin N. Baker

Background Pediatric palliative care (PPC) is “aimed at enhancing quality of life, promoting healing, and attending to suffering in children” 1 affected by life-limiting, chronic, or life-threatening illness. 2 – 4 The movement to formally

Full access

Loyda Amor N. Cajucom, Rita C. Ramos, Raymund Kernell B. Mañago, Raya Kathreen T. Fuentes, Primo G. Garcia, Queenie R. Ridulme, Myra DP. Oruga, and Maria Joanna G. Viñas

Background: Around 200,000 pediatric clients are diagnosed with cancer each year globally. Majority (84%) of cancer cases are found in developing countries with 20% average survival rate (Ferlay et al, 2012). Two-thirds of pediatric oncology

Full access

Elizabeth Stewart, Kaley Blankenship, Lauren Hoffmann, and Burgess Freeman

Background: The overall survival rate for children with solid tumors has plateaued over the past 2 decades and survival rates remain at or below 30% for children with recurrent or metastatic disease. This plateau comes at a time when pediatric

Full access

Xiaoqin Yang, Kaushal Desai, Neha Agrawal, Kirti Mirchandani, Sagnik Chatterjee, Eric Sarpong, and Shuvayu Sen

substantial morbidity including pain, motor dysfunction and disfigurement. There are currently no drug treatments approved for the treatment of PN. Real-world data among pediatric patients with NF1 and PN was limited. The objectives of this study were to

Full access

Joseph C. Alvarnas and Patrick A. Brown

for patients of all ages ( Figure 1 ). The foundation for improvements in survival outcomes for patients with ALL is data generated from rigorous, iterative clinical trials. Pediatric clinical trials, in particular, have been extraordinarily